key: cord-1043350-avao0a9i
authors: Mahalingasivam, Viyaasan; Craik, Alison; Tomlinson, Laurie A.; Ge, Long; Hou, Liangying; Wang, Qi; Yang, Kehu; Fogarty, Damian G.; Keenan, Ciara
title: COVID-19 and kidney transplantation: A systematic review
date: 2020-11-03
journal: Kidney Int Rep
DOI: 10.1016/j.ekir.2020.10.023
sha: ddb5c0bf5f953ff99fde03ce84880eab6559e6b0
doc_id: 1043350
cord_uid: avao0a9i

INTRODUCTION: Kidney transplant recipients are at increased susceptibility to many viral infections leading to justifiable anxiety about the effects of COVID-19. METHODS: We performed literature searches from multiple resources in April and August 2020 for relevant English and Chinese literature. Abstracts were screened, followed by full-text review with data extraction of reports that included at least 20 kidney transplant recipients with confirmed SARS-CoV-2 infection and completed outcomes. RESULTS: Twenty studies had sufficient data which we have summarised. Studies were predominantly descriptive and came from France, Italy, Spain, Turkey, UK, and USA. Quality assessment demonstrated limitations in selection of comparison groups and controlling for additional factors. Mortality rates from published studies were variable. Based on early data early from Spain, 46% of patients who developed COVID-19 within 60 days of transplantation died. Acute kidney injury was common, and mycophenolate was discontinued in most patients. CONCLUSION: Given the rapid global spread of COVID-19, reliable evidence is needed to inform public health policies. Hospitalised kidney transplant recipients with COVID-19 are at a high risk of death in early reports but interpretation of this data requires caution as studies were susceptible to period effects. Reassuringly, the quality of observational data is improving. Detailed and comprehensive data collection through linked registries will be necessary to conduct accurate analyses of risk factors for adverse outcomes, not least given the risks of stopping immunosuppression. This report highlights the early mortality excess in transplant recipients but medium and longer-term outcomes remain uncertain and merit careful investigation.

On 31 December 2019, the Wuhan Health Commission in China reported an outbreak of atypical pneumonia to the World Health Organisation (WHO). The causative pathogen was found to be the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) capable of human-to-human transmission through respiratory droplets. 1 The associated disease was named COVID-19, and its spectrum of severity ranges from no symptoms to life-threatening organ dysfunction, the scale of which can place extreme burden on healthcare resources without control of transmission. 2 After spread across several continents, COVID-19 was declared a pandemic by the WHO on 11 March 2020.

Severe lung injury and other organ-threatening complications in COVID-19 are understood to be the result of a dysregulated systemic inflammatory response in the days after infection leading to some immunosuppressive therapies being repurposed both inside and out of clinical trial settings in conventional management. [3] [4] [5] Only low-dose dexamethasone has so far demonstrated mortality benefit compared to usual practice. 6 Immunosuppressant drugs used to prevent allograft rejection render kidney transplant recipients at increased susceptibility to many viral infections and such infections are an important cause of morbidity and mortality in this population. 7 The immune response to SARS-CoV-2 infection in immunosuppressed kidney transplant recipients, many with other comorbidities, may result in differences in presentation, outcomes and therapeutic responses compared to the general population.

Given the rapid & global spread of COVID-19, there is a need to gather evidence and disseminate as quickly as possible. Our aim was to conduct a complete systematic review of the early literature to synthesise, analyse and appraise what has been learnt so far to help clinicians and policy makers better understand the risks to kidney transplant recipients, as well as identify gaps for future collaborative research for this global health challenge.

Inclusion and exclusion criteria were formulated to ensure comprehensive searching and screening for articles relevant to COVID-19 in chronic kidney disease (CKD), specifically including kidney transplantation. Variables of interest were defined based on the PICOS strategy. 8 Our protocol was prospectively published via PROSPERO (CRD42020182134).

Initial searches were conducted on 28 April 2020 including all relevant English and Chinese language research up to that date from 1 December 2019; papers not written in these languages were excluded due to a lack of resources to obtain timely translation. Published and non-published literature was searched on MEDLINE (Ovid), EMBASE (Ovid), China National Knowledge Infrastructure, the Wanfang database, the Chinese Biomedical Literature Database, clinicaltrials.gov, the Chinese Clinical Trial Register, the WHO database of COVID-19 research and the Chinese Medical Journal Network. Search terms are listed in Supplementary Material S1. An update search was deemed necessary due to the rapidly evolving evidence base and was conducted on the 4 August 2020 via MEDLINE (Ovid), EMBASE (Ovid), World Health Organisation COVID19 database, and bioRxiv and medRxiv preprint servers. The strategy for the update searches is attached in Supplementary Material S2.

Duplicates were removed from the studies generated by both searches and remaining studies were imported to the SysRev Platform (https://sysrev.com). Screening was undertaken at abstract level by separate teams of two independent authors for both English and Chinese; a senior author adjudicated where there was non-concordance. Reference lists were hand-searched for any additional studies that may have been missed. Full-text articles were then further assessed for eligibility including the exclusion of case reports or studies with populations of interest of fewer than 20 confirmed cases. As all studies were observational, further quality assessment was undertaken using the Newcastle-Ottawa Quality Assessment Scale. 9 Where articles did not report all outcomes specifically in kidney transplant populations, we contacted authors to request disaggregated data (Supplementary Material S3).

Data was extracted for each included study including online publication date, study population, timeframe, total number of cases (including how many patients had completed outcomes i.e. death or recovery to discharge), patient characteristics, clinical presentation, outcomes, baseline immunosuppression adjustment, and COVID-19 therapy. Inpatient mortality for each study was calculated as a proportion of patients with completed outcomes.

J o u r n a l P r e -p r o o f

PRISMA flow diagram is shown in Figure 1 . A total of 1,377 studies were identified through database searching, after which 762 remained after de-duplication; of these, a further 695 were excluded after abstract screening, leaving 65 which met criteria for full-text assessment for eligibility with no additional articles identified after hand-searching reference lists. A further 47 studies were excluded after detailed assessment. To be more comprehensive, we included two additional studies published shortly after our search was completed. 10, 11 In total, 20 studies underwent data extraction.

There were no randomised-controlled trials or case-control studies. Comparative analysis between different exposure groups was limited. Sánchez-Álavarez et al was a report from a national COVID-19 registry across Spain, 12 while Pascual et al and Pérez-Sáez et al reported on subgroups from this registry (those within 60 days of transplantation, and those treated with tocilizumab respectively). 13, 14 Bell et al and Ravanan et al reported from national transplant registries in Scotland and England respectively, while Manganaro et al reported on from a regional registry in Italy. 11, 15, 16 Kates et al reported on data entered to a registry by over 50 transplant centres, almost all from the USA, 10 while Cravedi et al was a report of a consortium registry of 12 transplant centres across USA, Italy and Spain. 17 Boyarsky et al and Vistoli et al were cross-sectional reports of national surveys from USA and Italy respectively. 18, 19 The remaining studies were either single-centre or small multicentre case series of either inpatients, or both inpatient and outpatient kidney transplant recipients with COVID-19. Using death as the main outcome of interest, formal quality assessment is shown in Table 1 using the Newcastle-Ottawa Quality Assessment Scale. 9 Quality assessment demonstrated consistent weaknesses in selection of control groups (e.g. home dialysis patients on the transplant waiting list) and inadequate control for additional confounding factors. Case series are descriptive and do not make comparisons with a control group, while singlecentre reports may yield biased results when compared to the source population. Kates et al was susceptible to selection bias as participating centres may not have systematically submitted all cases. 10 Some studies did not report how many patients had been discharged meaning mortality estimates may have been inaccurate due to misclassification of cases who died after the end of follow-up but more recent reports had longer and more complete follow-up. While Boyarsky et al and Vistoli et al had high response rates to their surveys, they may not be completely reliable as they were not linked to individual patient records. 18, 19 Italy, Spain, Turkey, UK and USA); at least five of the seven studies with patients from USA included cases from New York City. There have been smaller published studies not included in our review from Belgium, China, Iran, Netherlands, Portugal, and Switzerland.

We note that some studies had overlapping cohorts: patients from Mohamed et al would be included in Ravanan et al, 11, 20 [12] [13] [14] 23 Cravedi et al excluded any patients from studies which had already been published but these were smaller studies not included in our summary. 17 Kates et al did not report which centres submitted data to its registry but there were over 50, of whom >98% were from the USA; 10 our review includes six other studies with data from USA which may have overlapped. Some centres from USA and Italy reported in our review are likely to have contributed to the surveys published by Boyarsky et al and Vistoli et al. 18, 19 

Data and results from each study are summarised in Table 2 . The 20 studies were published online between 10 April and 11 August 2020; one was a preprint with the remainder in journals. The last day of follow-up for each study ranged from 17 March to 31 May 2020. The studies ranged from 24 to 489 kidney transplant recipients in total.

Of the studies with available patient demographic data, average age ranged from 45 years in Demir et al to 66 years in 24 The percentage of male patients ranged from 46% in Pascual et al to 79% in Bossini et al. 13, 25 Clinical presentation Fever was common in studies, ranging from 52% to 95%; cough ranged from 49% to 78%, and dyspnoea from 28% to 70%. Gastrointestinal symptoms were also reported, as high as 53% in Chaudhry et al. 26 Four studies reported data on AKI or graft dysfunction at presentation, ranging from 28% in Mohamed et al to 77% in Chen et al. 20, 27 No report described asymptomatic infection.

A wide range of approaches were taken to adjust immunosuppression both between and within the studies. The dominant practice across other studies was to favour withholding or reducing J o u r n a l P r e -p r o o f antiproliferative drugs or mammalian target of rapapmycin inhibitor (mTORi) over reduction in CNI dose.

Thirteen studies reported the use of COVID-19 therapies. Hydroxychloroquine was used in 11 studies, either alone or in combination with another therapy, with the proportion of patients receiving the drug ranging from 38% to 100%. Ten studies either started corticosteroid therapy or increased dosage. High dose corticosteroid was reported in six studies for between 4% and 62% of patients. Remdesivir use was reported in only a few studies, in a small number of patients. Eleven studies reported the use of an anti-IL-6 therapy. Pérez-Sáez et al described the experience of tocilizumab use based on inpatient cases entered to the Spanish Society of Nephrology registry.

Inpatient mortality was calculated where possible as a proportion from patients with completed outcomes (i.e. death or recovery to discharge), with the intention of reducing bias by misclassification of patients who remain hospitalised but may die later. In the largest national registry reports, mortality was 43% amongst mostly inpatients with completed outcomes in Sánchez-Álvarez et al from Spain up until 11 April, and 26% in mostly inpatients reported by Ravanan et al from England up until 20 May, although the number of patients who may subsequently recover from both studies was not known. 11, 12 In the largest multicentre series, Cravedi et al reported 32% mortality in 144 inpatients although it did not specify how many recovered to discharge, while Kates Cravedi et al found 7% increased mortality in people aged >60 years compared to those aged ≤60 years. 17 In subgroup reports from the national registry in Spain, Pascual et al reported 46% mortality amongst patients within 60 days of transplantation, while Pérez-Sáez reported 33% mortality amongst patients with severe COVID-19 treated with tocilizumab. 13, 14 The proportion of patients requiring intensive care was variable, from 9% of inpatients across Spain according to early registry data, 12 to 42% of inpatients in the large multicentre series report by Kates et al including 34% requiring mechanical ventilation. 10 AKI was common, ranging from 41% in Kates et al with 13% requiring extracorporeal renal replacement therapy (RRT), to 53% in Mehta et al although none required RRT. 10,28 There were very few reports of acute rejection with only one case out of 318 in Kates et al. 10 Benotmane reported RNAaemia in 26% and seropositivity in 100% of survivors. 29 J o u r n a l P r e -p r o o f Discussion Our systematic review of the early literature up to 11 August 2020 suggests that kidney transplant recipients hospitalised with COVID-19 experience poor outcomes, especially in the early posttransplant period.

The limitations of the literature so far require appreciation. Over time, published studies evolved from reports from a small number of centres, to larger multi-centre studies and national registries. To reduce bias by smaller studies, we only reported those studies with completed outcomes for at least 20 kidney transplant recipients with confirmed COVID-19. Small studies may be more likely to be published by centres who accumulate more complex or unwell patients or by centres who are affected particularly unfavourably, both of which may introduce important bias; they may also exert a period effect, reflecting more overwhelming circumstances in the earlier stages of the pandemic.

Variation in reported mortality could also be due to strong period effects, with differences in thresholds for hospitalisation, availability of resources, and management practices. Data from Sánchez-Álvarez et al found mortality of 43% from the Spanish Society of Nephrology COVID-19 registry in which 94% were inpatients. 12 However, this is likely to be exaggerated as this was an early report based on data reported up to 11 April, and around 147 cases remained alive but not yet recovered so were not included in our mortality calculation; fewer patients were admitted to ICU compared to other reports which may also be an important period effect related to stretched resources.

The other large national registry report was Ravanan et al, who identified all solid organ transplant recipients from the National Health Service (NHS) Blood and Transplant (NHSBT) and linked this to confirmed COVID-19 cases through Public Health England and the NHS Digital Tracing Service. 11 Of over 30000 prevalent kidney-or kidney-pancreas recipients in England, there were 489 cases of COVID-19 of whom 128 died (26%) up to 20 May. 11 This was compared to deaths in 18/188 (10%) patients waitlisted for transplant but this comparison should be treated with caution as many of these will have been in-centre haemodialysis patients with more access to testing for milder or asymptomatic disease than transplant recipients in the community during the period of study. It was not possible to distinguish inpatients and outpatients from the available data sources but as data was collected up to 20 May, most cases were likely to be inpatients.

Large multicentre series were published by Cravedi et al and Kates et al. Cravedi et al reported data for inpatients with COVID-19 from centres in Italy, Spain and USA already participating in the TANGO consortium, an international network formed initially to investigate the recurrence of glomerular disease after transplantation. 17 Kates et al reported outcomes from a registry hosted by the University of Washington to which cases were submitted from >50 centres, >98% of which were from USA after invitations through the American Society of Transplantation and American Society of Transplant Surgeons. 10 Entered data was not independently verified and its representativeness is uncertain as the extent to which cases from participating centres were systematically submitted is not known with the authors acknowledging susceptibility to bias.

Studies from USA reported high proportions of black patients although no study investigated for associations between ethnicity or other socioeconomic factors with outcomes. From all solid organ transplant recipients in England, 38/129 Asian recipients (30%) and 27/95 (28%) black recipients died, compared to 79/334 white recipients (24%). In total, 2.4% of Asian recipients and 3.6% of black recipients have been diagnosed with COVID-19, compared to 1.0% of white recipients. 11

The withdrawal of antiproliferative drugs such as mycophenolate, an inhibitor of T-and B-cell proliferation, was practiced almost universally, in keeping with expert consensus for even mild disease. 30,31 Our review highlighted the myriad of different management strategies used in different centres, including antivirals, hydroxychloroquine, corticosteroids, and tocilizumab. Establishing the effectiveness of therapies requires well-designed clinical trials; as high-risk patients, kidney transplant recipients may benefit from both prophylactic and therapeutic trials. The RECOVERY trial demonstrated mortality benefit in treatment with dexamethasone 6mg daily for patients with COVID-19 requiring oxygen in June 2020, with the WHO consequently recommending the use of systemic corticosteroids in severe and critical cases. 6, 32 The RECOVERY trial has stopped recruiting patients to its lopinavir/ritonavir arm due to lack of benefit. 33 Few patients in studies were reported to have been treated with remdesivir.

AKI was seen in several studies although it not all studies reported their definition and alternative terminology such as "renal failure" was also mentioned. AKI is not uncommon in COVID-19 and its pathophysiology remains uncertain but direct parenchymal infection and microangiopathy mediated by complex inflammatory processes have been suggested. 34 In transplant kidneys, there may be additional mechanisms such as acute rejection from underimmunosuppression, or CNI toxicity through drug-drug interactions (e.g. lopinavir/ritonavir). However, there were few reports of acute rejection in our review but there may have been less investigation for this due to unwillingness to augment immunosuppression if it were diagnosed; we did not identify any histopathological series; case reports of biopsies are prone to bias so systematic cross-sectional or longitudinal study designs would need to be considered. Studies in the coming months and years will need to address the longer-term impact of COVID-19 on graft function and permanent graft loss.

As the pandemic continues, we will need to utilise more systematic national and international registries with appropriate control groups and linkage to other sources such as community test results and hospital records, to allow timely, large scale analyses which can better inform policies and practices. Serological surveys of transplant recipients using validated antibody assays could be valuable in capturing the prevalence of asymptomatic and mild infection which did not result in inpatient admission or community viral RNA testing; such surveys will be important to obtain more accurate mortality and hospitalisation estimates, follow-up potential longer term complications, and identify the factors which are associated with more favourable outcomes.

In the absence of available data, we were unable to undertake time-to-event analysis, therefore we report mortality as a proportion of patients with completed outcomes to avoid misclassification of patients who remain hospitalised but may die after surviving the study period. However, this might be biased in the opposite direction if most of those who remained hospitalised were patients who were slowly recovering and more likely to survive.

Our searches only included studies in English or Chinese, with studies meeting inclusion criteria from France, Italy, Spain, Turkey, UK, and USA only. Searches in more languages may have resulted in a broader perspective including more experiences in middle-income economies. As well as studies from Europe and North America, there were studies published from China and Iran from early in the pandemic which did not fulfil our criteria for inclusion due to smaller numbers of confirmed cases. It would be beneficial to obtain updated reports from centres such as these, as well as others in Africa, Asia and Latin America.

The Newcastle-Ottawa Quality Assessment Scale was of limited value in objective quality assessment. It is designed to be semi-quantitative but the crude equivalence of all the constituent assessment items may be misleading.

Our review of the literature in the early phase of the COVID-19 epidemic suggests that hospitalised kidney transplant recipients with COVID-19 are at a high risk of death. The quality of observational data is improving. Detailed and comprehensive data collection through registries and linkage with health records will be necessary to conduct analyses of risk factors for adverse outcomes, not least given the risks of stopping immunosuppression. Indeed, to optimise clinical care, we should ensure that non-hospitalised patients are included and existing registries are supported and commissioned to answer important questions that impact screening and management.

We are reassured that we have developed a reproducible search strategy that can be effectively redeployed at appropriate intervals during the pandemic and beyond to be able to conduct metaanalyses of accumulating data in future.

J o u r n a l P r e -p r o o f Disclosures Insilica, LLC, owners of Sysrev, gifted the review team a grant worth $2000 total to support screening and data extraction. This research did not receive any other specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Supplementary Material S1 -Initial search (PDF) Inpatients only:

• Time from symptoms to presentation (days) median 7 (IQR 4-10) • WCC (10 9 /l) median • Neutrophils (10 9 /l) median 4.1 (IQR 2.9-6.8) • Lymphocytes (10 9 /l) median 0.6 (IQR 0. 

Early transmission dynamics in Wuhan, China, of novel coronavirusinfected pneumonia

Disease and healthcare burden of COVID-19 in the United States

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations

Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Infection-Related Mortality in a Large Cohort of Renal Transplant Recipients

• BMI (kg/m2) median 30 (IQR 24-33)

cardiovascular disease 16/40 (40%), respiratory disease 9/40 (23%)

• Time since kidney transplant (years) median 7

• Induction IS: ATG 18/40 (44%)

ciclosporin 14/40 (35%), MMF/MPA 34/40 (85%), mTORi 6/40 (15%)

• Fever 38/40 (95%) • Cough

 Table 1 Description of each study design and quality assessment using the Newcastle-Ottawa Quality Assessment Scale, listed by order of online publication date. From left to right, quality items were starred black if they fulfilled pre-defined criteria: selection was starred on representativeness of patients with the exposure of interest (kidney transplant), selection of the non-exposed group, ascertainment of exposure, and demonstration that outcome of interest (death) was not present at start of the study; comparability was starred on the study controlling for the exposure of interest, and any additional factor; outcome was starred on how the outcome was assessed, whether followup was long enough for the outcome to occur, and whether loss to follow-up was adequate enough to be unlikely to introduce bias.

Summary of clinical data and outcomes from all included studies listed by order of online publication date.